OOIR: Observatory of International Research

Papers

(The median citation count of Current Opinion in Lipidology is 2. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-11-01 to 2024-11-01.)

Article	Citations
Mendelian randomization as a tool for causal inference in human nutrition and metabolism	46
Very long-chain saturated fatty acids and diabetes and cardiovascular disease	40
CD36 (SR-B2) as master regulator of cellular fatty acid homeostasis	39
ANGPTL3 as therapeutic target	38
Lipids and peripheral neuropathy	29
Impact of ultra-processed food consumption on metabolic health	29
Update on apolipoprotein B	28
Omega-3 fatty acids and cognitive function	25
Management of familial hypercholesterolemia in pregnancy	25
Inhibition of angiopoietin-like 3 for the management of severe hypercholesterolemia	24
Triglyceride-rich lipoproteins, remnant-cholesterol, and atherosclerotic cardiovascular disease	24
Lipids and brain inflammation in APOE4-associated dementia	23
Depression and cardiovascular disease	23
Extracellular matrix: paving the way to the newest trends in atherosclerosis	23
The impact of race and ethnicity on lipoprotein(a) levels and cardiovascular risk	23
Vascular stiffening and endothelial dysfunction in atherosclerosis	23
Consensus and guidelines on lipoprotein(a) – seeing the forest through the trees	22
Small dense low-density lipoprotein particles: clinically relevant?	21
The clinical applicability of polygenic risk scores for LDL-cholesterol: considerations, current evidence and future perspectives	21
Characteristics of plaque lipid-associated macrophages and their possible roles in the pathogenesis of atherosclerosis	20
Update on cerebrotendinous xanthomatosis	18
The expanding role of lyso-phosphatidylcholine acyltransferase-3 (LPCAT3), a phospholipid remodeling enzyme, in health and disease	18
Familial combined hyperlipidemia is a polygenic trait	15
Understanding the ins and outs of lipoprotein (a) metabolism	15
Lipid effects of glucagon-like peptide 1 receptor analogs	14

The iterative lipid impact on inflammation in atherosclerosis	14
HDL and persistent inflammation immunosuppression and catabolism syndrome	13
Dyslipidemia and aortic valve disease	12
Sphingosine-1-phosphate: metabolism, transport, atheroprotection and effect of statin treatment	12
Angiopoietin-like proteins and postprandial partitioning of fatty acids	11
Polygenic scores for dyslipidemia: the emerging genomic model of plasma lipoprotein trait inheritance	11
The role of gut-derived oxidized lipids and bacterial lipopolysaccharide in systemic inflammation and atherosclerosis	11
Metabolic dysfunction-associated fatty liver disease: advances in genetic and epigenetic implications	11
New algorithms for treating homozygous familial hypercholesterolemia	11
Recent advances in ABCG5 and ABCG8 variants	11
The need for polygenic score reporting standards in evidence-based practice: lipid genetics use case	11
Cardiovascular risk in patients with nonalcoholic fatty liver disease: looking at the liver to shield the heart	11
Polygenic risk scores: how much do they add?	11
ANGPTL4: a new mode in the regulation of intravascular lipolysis	11
Nonalcohol fatty liver disease: balancing supply and utilization of triglycerides	11
Dietary factors and brain health	10
How should low-density lipoprotein cholesterol be calculated in 2022?	10
Translating guidelines into practice via implementation science: an update in lipidology	9
Can we revive CETP-inhibitors for the prevention of cardiovascular disease?	9
Therapeutic application of genome editing in dyslipidemia	9
Lipid effects of sodium-glucose cotransporter 2 inhibitors	9
Recent lipoprotein(a) trials	8
The genetic counselor's role in management of patients with dyslipidemia	8
Proprotein convertase subtilisin/kexin type 9 inhibition after acute coronary syndrome or prior myocardial infarction	8
Genetic determinants of pancreatitis: relevance in severe hypertriglyceridemia	7
Evolving ANGPTL-based lipid-lowering strategies and beyond	7
Sphingomyelins and ceramides: possible biomarkers for dementia?	7
Cross-species data integration to prioritize causal genes in lipid metabolism	7
Links between ceramides and cardiac function	7
Role of VLDL receptor in atherogenesis	7
New insights in statins affecting atheromatous plaque macrophages	7
Lipidomics in gestational diabetes mellitus	7
Metabolic regulation of macrophage proliferation and function in atherosclerosis	7
Fatty liver and cerebrovascular disease: plausible association and possible mechanisms	7
Impact of metabolic dysfunction on cognition in humans	6
Recent Apolipoprotein CIII trials	6
Current models of apolipoprotein A-I lipidation by adenosine triphosphate binding cassette transporter A1	6
Considerations for routinely testing for high Lp(a)	6
Dietary fat and carbohydrate affect the metabolism of protein-based high-density lipoprotein subspecies	6
Association of dietary patterns and components with atherosclerosis risk biomarkers in familial hypercholesterolemia	6
Liver fat storage pathways: methodologies and dietary effects	6
Inflammation compared to low-density lipoprotein cholesterol: two different causes of atherosclerotic cardiovascular disease	6
Macrophage SR-B1 in atherosclerotic cardiovascular disease	5
Lipid metabolism during pregnancy: consequences for mother and child	5
Early atherogenesis: new insights from new approaches	5
Inclisiran: present and future perspectives of a new effective LDL cholesterol-lowering agent	5
Assessment of atherosclerosis: should coronary calcium score and intima-media thickness be replaced by ultrasound measurement of carotid plaque burden and vessel wall volume?	5
Circulating protein and lipid markers of early sepsis diagnosis and prognosis: a scoping review	5
Deep dive to the secrets of the PREDIMED trial	5
Cascade screening for familial hypercholesterolemia should be organized at a national level	5

Familial hypercholesterolemia: The nexus of endothelial dysfunction and lipoprotein metabolism in COVID-19	5
Oxidized LDL receptors: a recent update	5
Apolipoprotein genetic variants and hereditary amyloidosis	4
Novel therapeutic opportunities for familial lecithin:cholesterol acyltransferase deficiency: promises and challenges	4
Lipids and cardiovascular calcification: contributions to plaque vulnerability	4
The role of the molecular circadian clock in human energy homeostasis	4
Use of apheresis in the age of new therapies for familial hypercholesterolaemia	4
Lymphatics - not just a chylomicron conduit	4
Diagnosis of remnant hyperlipidaemia	4
Angiopoietin-like protein 3 inhibitors and contemporary unmet needs in lipid management	4
Assessment of cardiovascular disease risk: a 2023 update	4
Soy consumption, cognitive function, and dementia	4
Angiopoietin-like 3 inhibition and the liver: less is more?	4
Editorial: Discussing polygenic risk with lipid clinic patients	4
ANGPTL3 and ApoC-III inhibitors for treating hypertriglyceridemia in context: horses for courses?	3
The feedback cycles between glucose, amino acids and lipids and alpha cell secretion and their role in metabolic fatty liver disease	3
Pharmacogenomics of statins and familial hypercholesterolemia	3
The power of lipid registries for cardiovascular disease prevention	3
Ups and downs in PCSK9 inhibition in the cardiovascular arena: a review	3
Mechanisms of nonalcoholic steatohepatitis-associated cardiomyopathy: key roles for liver–heart crosstalk	3
A new SPRING in lipid metabolism	3
Genetic variants associated with cardiovascular diseases and related risk factors highlight novel potential therapeutic approaches	3
Angiopoietin-like protein 8: a multifaceted protein instrumental in regulating triglyceride metabolism	3
Editorial comment: when Mendelian randomization goes astray	3
PCSK9-directed therapies: an update	3
The multiple roles of lysophosphatidic acid in vascular disease and atherosclerosis	3
Genotype–phenotype correlation in a large cohort of pediatric patients with heterozygous and homozygous familial hypercholesterolemia	3
LDL receptor-related protein 1 and its interacting partners in tissue homeostasis	3
Recent dynamic studies of the metabolism of atherogenic lipoproteins: elucidating the mode of action of new therapies	3
Basic and translational evidence supporting the role of TM6SF2 in VLDL metabolism	2
Regulation of cardiovascular calcification by lipids and lipoproteins	2
Predictors of cardiovascular risk in familial hypercholesterolemia	2
Resolution of apolipoprotein A1 and A2 proteoforms: their cardiometabolic correlates and implications for future research	2
Strategies of improving adherence to lipid-lowering therapy in patients with atherosclerotic cardiovascular disease	2
Atherosclerosis: cell biology and lipoproteins	2
Atherosclerosis: cell biology and lipoproteins	2
Bempedoic acid for nonalcoholic fatty liver disease: evidence and mechanisms of action	2
Competing tissue-specific functions for the Tribbles-1 plasma lipid associated locus	2
Editorial comment: hazards of interpreting genetic reports	2
Clinical associations between exercise and lipoproteins	2
Polygenic contribution for familial hypercholesterolemia (FH)	2
The impact of atherosclerotic cardiovascular disease, dyslipidaemia and lipid lowering therapy on Coronavirus disease 2019 outcomes: an examination of the available evidence	2
Considerations for routinely testing for high lipoprotein(a)	2
Cholesterol 25-hydroxylase expression following immune activation in response to SARS-CoV-2 infection	2
Nonalcoholic fatty liver disease: an update	2
The clinical utility of polygenic risk scores for combined hyperlipidemia	2
Lipoprotein (a) in familial hypercholesterolaemia	2
Macrophage inflammarafts in atherosclerosis	2
Circulating cell-free DNA and its association with cardiovascular disease: what we know and future perspectives	2